LAIR1 and acute myeloid leukemia: Given its expression on most immune cells, and its inhibitory properties and regulatory role, LAIR-1 is thought to be a potential therapeutic target for diseases including acute myeloid leukemia and other cancers, as well as inflammatory diseases such as fibrosis and arthritis (Kang et al., 2015, 2016; Agashe et al., 2018; Park et al., 2020).